Atlas Trials

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

Clinical trial NCT06503731 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06503731
Sponsor
argenx
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Antibody-mediated Rejection
Start date
2024-08-30
Primary completion
2027-11-01
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.